Kelly E. McCann, MD, PhD

Kelly E. McCann, MD, PhD, is an assistant professor and breast medical oncologist at UCLA.

Articles by Kelly E. McCann, MD, PhD

Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

ByKelly E. McCann, MD, PhD,Sara A. Hurvitz, MD, FACP ,Virginia Kaklamani, MD,Mark D. Pegram, MD

July 8th 2024

A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

ByKelly E. McCann, MD, PhD,Sara A. Hurvitz, MD, FACP ,Virginia Kaklamani, MD,Mark D. Pegram, MD

July 1st 2024

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

ByKelly E. McCann, MD, PhD,Sara A. Hurvitz, MD, FACP ,Virginia Kaklamani, MD,Mark D. Pegram, MD

July 1st 2024

A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.

Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

ByKelly E. McCann, MD, PhD,Sara A. Hurvitz, MD, FACP ,Virginia Kaklamani, MD,Mark D. Pegram, MD

June 25th 2024

Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.

Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

ByKelly E. McCann, MD, PhD,Sara A. Hurvitz, MD, FACP ,Virginia Kaklamani, MD,Mark D. Pegram, MD

June 25th 2024

Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

ByStephanie L. Graff, MD, FACP,Reshma L. Mahtani, DO,Kelly E. McCann, MD, PhD,Hope S. Rugo, MD

April 11th 2024

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

Kelly E. McCann, MD, PhD

Articles by Kelly E. McCann, MD, PhD

Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma